BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36621463)

  • 1. Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis.
    Swaby J; Aggarwal A; Batra A; Jain A; Seth L; Stabellini N; Bittencourt MS; Leong D; Klaassen Z; Barata P; Sayegh N; Agarwal N; Terris M; Guha A
    Clin Genitourin Cancer; 2023 Jun; 21(3):e182-e189. PubMed ID: 36621463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Crawley D; Adolfsson J; Rudman S; Van Hemelrijck M
    PLoS One; 2015; 10(3):e0117344. PubMed ID: 25794005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.
    Liang Z; Zhu J; Chen L; Xu Y; Yang Y; Hu R; Zhang W; Song Y; Lu Y; Ou N; Liu X
    Andrology; 2020 May; 8(3):559-574. PubMed ID: 31743594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
    Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
    Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
    JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.
    Rudman SM; Gray KP; Batista JL; Pitt MJ; Giovannucci EL; Harper PG; Loda M; Mucci LA; Sweeney CJ
    BJU Int; 2016 Dec; 118(6):919-926. PubMed ID: 26805930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.
    Nead KT; Sinha S; Yang DD; Nguyen PL
    Urol Oncol; 2017 Nov; 35(11):664.e1-664.e9. PubMed ID: 28803700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks of metabolic diseases and androgen deprivation therapy for prostate cancer in a Chinese population: a prospective multi-centre cohort study.
    Wong C; Chu P; Teoh J; Chiu P; Yee CH; Chau L; Chan M; Wan H; Leung S; Ng CF
    Int Urol Nephrol; 2022 May; 54(5):993-1000. PubMed ID: 35217907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of multidisciplinary interventions in preventing metabolic syndrome and improving body composition in prostate cancer patients treated with androgen deprivation therapy: A systematic review and meta-analysis.
    Yang U; Harikrishna A; Preda V; Chen J
    Clin Nutr ESPEN; 2023 Dec; 58():27-49. PubMed ID: 38057016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.
    Huang YB; Li WL; Sun M; Duan X; Wang YT; Zhang LX; Xin ZH; Yun ZF; Fan B; Li XC
    Asian J Androl; 2023; 25(3):366-374. PubMed ID: 35915542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.
    Wang H; Sun X; Zhao L; Chen X; Zhao J
    J Diabetes Investig; 2016 Jul; 7(4):629-36. PubMed ID: 27181717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data.
    Gomaa S; Kelly WK; Mitchell E; Storozynsky E; Zeigler-Johnson C; Juon HS; Wen KY
    World J Urol; 2023 Sep; 41(9):2351-2357. PubMed ID: 37555986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
    Liu R; Zhou J; Xia S; Li T
    Urol Int; 2020; 104(3-4):214-221. PubMed ID: 31747673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
    MacLennan S; Azevedo N; Duncan E; Dunsmore J; Fullwood L; Lumen N; Plass K; Ribal MJ; Roobol MJ; Nieboer D; Schouten N; Skolarus TA; Smith EJ; N'Dow J; Mottet N; Briganti A;
    Eur Urol; 2023 May; 83(5):393-401. PubMed ID: 36639296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.
    Nead KT; Sinha S; Nguyen PL
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):259-264. PubMed ID: 28349979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
    Lage MJ; Barber BL; Markus RA
    Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.